Mechanistically, this novel pan-PAD inhibitor suppressed H3 citrullination and activated p53 target gene expression, including SESN2, thereby inhibiting the downstream mTORC1 signaling pathway and interfering with autophagy to inhibit the proliferation of cancer cells [111,308]. The gene discussed is TP53; the disease is cancer.